Flindr

About Flindr

Flindr Therapeutics is a private, pre-clinical biotechnology company headquartered in Oss, the Netherlands, concentrated on creating next-generation precision oncology treatments. The company originated in 2020 as a spin-off from the Netherlands Cancer Institute (NKI) and the Oncode Institute, initially named Immagene. Its establishment is rooted in the extensive work of its founders: Prof. Daniel Peeper, Prof. Christian Blank, and Dr. Maarten Ligtenberg, who serve as the CEO. Dr. Ligtenberg brings over a decade of experience in oncology, particularly in immuno-oncology and cancer target identification. Prof. Peeper is a distinguished professor in Functional Oncogenomics and heads the Department of Molecular Oncology & Immunology at NKI. Prof. Blank is a medical oncologist and a group leader at NKI, with a research focus on combination immune checkpoint inhibition. This convergence of expertise in functional genomics, immunotherapy, and translational research forms the scientific bedrock of the company. Flindr's business model is centered on the discovery and development of a pipeline of first-in-class small molecule inhibitors for the precision treatment of cancer. The company's revenue generation will depend on the successful progression of its therapeutic candidates through pre-clinical and clinical trials, leading to potential licensing deals, partnerships with larger pharmaceutical companies, or future commercialization of approved drugs. The firm's primary clients are anticipated to be patients within specific oncology segments who can benefit from highly targeted therapies. In April 2024, the company secured €20 million in a Series A financing round to advance its lead program and expand its pipeline. The core of Flindr's operations is its proprietary 'ImmunoGram Drug Discovery Engine'. This platform is a sophisticated cascade of activities including target identification, validation, clinical bio-informatics, and druggability assessments. It functions by reverse-translating the clinical heterogeneity observed in patients' tumor and host immune factors into robust laboratory models. This allows for the screening and selection of critical drug targets involved in clinical response. Flindr's lead program, identified through this engine, is a first-in-class small molecule inhibitor targeting RNF31 (also known as HOIP), a protein-stabilizing E3 ubiquitin ligase that is aberrantly activated in various solid and hematological cancers. Pre-clinical studies have shown promising results in ovarian cancer and B-cell lymphoma models, and the company has identified biomarkers to help select patients most likely to respond to the treatment.